April 18, 2019

PET/CT radiotracer benefits clinicians, prostate cancer patients

18F-DCFPyL PSMA PET/CT imaging accurately localized biochemically recurrent prostate cancer and prompted clinicians to change their management plans in more than 80% of patients, according to a recent study in the Journal of Nuclear Medicine. {read more here}